Cipla Vice Chair Explores Lung Leadership Vision With Biosimilars Opportunities
Samina Hamied Also Discusses Industry’s Expectations From Indian Government
Executive vice chairperson of Cipla Samina Hamied talks to Generics Bulletin about the company’s intention to become global lung leaders on the back of biosimilars opportunities and its inhalation assets. As well as discussing Cipla’s three-year strategy, Hamied – who is also the vice president of IPA – discusses creating a favorable regulatory and policy landscape in India.
